Uveal metastasis in 1111 patients: Interval to metastasis and overall survival based on timing of primary cancer diagnosis.

Breast cancer Eye Lung cancer Metastasis Uvea

Journal

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
ISSN: 1319-4534
Titre abrégé: Saudi J Ophthalmol
Pays: India
ID NLM: 9425601

Informations de publication

Date de publication:
Historique:
received: 25 01 2019
accepted: 08 07 2019
entrez: 6 11 2019
pubmed: 7 11 2019
medline: 7 11 2019
Statut: ppublish

Résumé

To evaluate interval between primary cancer diagnosis and uveal metastasis and assess survival outcomes based on whether the primary cancer was diagnosed before or after uveal metastasis. In this retrospective analysis, all patients with uveal metastasis evaluated on the Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, USA between February 1, 1974 and June 1, 2017 were included. Features and outcomes based on timing of primary cancer diagnosis, whether before or after diagnosis of uveal metastasis, were assessed. A total of 2214 uveal metastases were diagnosed in 1310 eyes of 1111 consecutive patients. Primary cancer was known prior to uveal metastasis in 742 patients (67%) and not known in 369 (33%). Of those not known, the primary cancer was later found in 192 patients (17%) and never found in 177 patients (16%). For those with known primary cancer, mean interval from primary cancer diagnosis to uveal metastasis was 5.2 years with differences in primary sites of gastrointestinal (2.1 years, p = 0.003), lung (2.2 years, p < 0.001), breast (6.5 years, p < 0.001), and thyroid (13 years, p < 0.001). By Kaplan-Meier analysis, the 5-year overall survival showed no difference between patients with primary cancer found before (28%) vs after (20%) vs never found (33%), relative to uveal metastasis. Of 1111 patients with uveal metastasis, early-onset uveal metastases were found with lung and gastrointestinal tract cancers, whereas late-onset metastases were found with breast and thyroid cancers. Overall survival did not vary on whether the primary tumor was diagnosed before, after, or never found, relative to uveal metastasis.

Identifiants

pubmed: 31686963
doi: 10.1016/j.sjopt.2019.07.006
pii: S1319-4534(19)30043-8
pmc: PMC6819751
doi:

Types de publication

Journal Article

Langues

eng

Pagination

229-237

Informations de copyright

© 2019 The Authors.

Références

Arch Ophthalmol. 1985 Jul;103(7):937-40
pubmed: 4015484
Chest. 2013 May;143(5 Suppl):e78S-e92S
pubmed: 23649455
Ophthalmology. 2014 Jan;121(1):352-357
pubmed: 23988200
Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):81-90
pubmed: 30122853
Am J Ophthalmol. 2003 Aug;136(2):264-71
pubmed: 12888048
Ophthalmology. 1994 Jun;101(6):1084-90
pubmed: 8008351
Br J Ophthalmol. 2014 Jan;98(1):92-8
pubmed: 24169654
Thyroid. 2013 May;23(5):543-51
pubmed: 23082768
Arch Ophthalmol. 1974 Oct;92(4):276-86
pubmed: 4412321
Cancer Growth Metastasis. 2015 Nov 29;8:43-9
pubmed: 26640389
Ophthalmology. 1979 Jul;86(7):1336-49
pubmed: 233866
Retina. 2020 Feb;40(2):204-213
pubmed: 31972789
Cancer Res. 2015 Dec 1;75(23):5014-22
pubmed: 26354021
Am J Ophthalmol. 1995 Apr;119(4):422-30
pubmed: 7709967
Ophthalmology. 2011 Jul;118(7):1483-1483.e4
pubmed: 21724049
Cornea. 2015 Jan;34(1):42-8
pubmed: 25343701
Ophthalmology. 1997 Aug;104(8):1265-76
pubmed: 9261313
Arch Ophthalmol. 1987 Sep;105(9):1215-9
pubmed: 3307718
Indian J Ophthalmol. 2015 Feb;63(2):122-7
pubmed: 25827542

Auteurs

R Joel Welch (RJ)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Kunal Malik (K)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Eileen L Mayro (EL)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Jennifer H Newman (JH)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Stephanie E Honig (SE)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Su Mae Ang (SM)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Evan B Selzer (EB)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Luis A Acaba-Berrocal (LA)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Mark P McGarrey (MP)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Alexander E Graf (AE)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Sean P Considine (SP)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Jerry A Shields (JA)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Carol L Shields (CL)

The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States.

Classifications MeSH